Increasing prevalence of anxiety and depression, coupled with innovation in pharmaceutical treatments and growing demand for mental health solutions, fuels growth in the anxiety disorders and ...

A Duloxetine recall by the FDA has flagged more than 7,100 bottles of the Cymbalta generic drug due to a cancerous chemical.

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...

Anxiety and depression are more common among people with Crohn’s disease, and they can worsen symptoms. Here’s why and ways ...

He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized ... and neurological disorders, having contributed to the successful ...

We are delighted to welcome Dr. Barbato to Incannex as our Chief Medical Officer. With an established track record in directing drug development through late-stage clinical trials and multiple product ...

Most of us have experienced anxiety or will at some point in the future. It's normal to feel worried from time to time.

A prescription digital therapeutic for insomnia was associated with significant improvements in sleep, depression, and anxiety.

Global Cannabis Use Disorder Treatment Market. The global cannabis use disorder treatment market is expected to grow from USD ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...